| 製品コード |
製品名称 |
製品説明 |
参考文献 |
|
S4430
|
Hydroxychloroquine (HCQ) Sulfate
|
Hydroxychloroquine (HCQ) Sulfate is an antimalarial agent used for the treatment of systemic lupus erythematosus, rheumatoid arthritis and other autoimmune, inflammatory and dermatologic conditions. Also acts as an inhibitor of autophagy and toll-like receptor (TLR) 7/9.
|
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
|
|
S2853
|
Carfilzomib (PR-171)
|
Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities. Carfilzomib activates prosurvival autophagy and induces cell apoptosis.
|
Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study
|
|
S7975
|
Favipiravir (T-705)
|
Favipiravir (T-705) is a potent and selective RNA-dependent RNA polymerase inhibitor, used to treat influenza virus infections.
|
Discovering drugs to treat coronavirus disease 2019 (COVID-19)
|
|
S1835
|
Azithromycin
|
Azithromycin is an antibiotic by inhibiting protein synthesis, used for the treatment of bacterial infections.
|
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
|
|
S1620
|
Darunavir Ethanolate
|
Darunavir Ethanolate (TMC-114, UIC 94017) is a nonpeptidic HIV protease inhibitor, used to treat HIV infection.
|
Many drugs already approved by FDA may have promise against COVID-19
|
|
S4646
|
Ciclesonide
|
Ciclesonide (Alvesco, Omnaris, RPR251526, Zetonna) is a glucocorticoid used to treat obstructive airway diseases.
|
Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: Report of three cases
|
|
S3035
|
Daunorubicin HCl
|
Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM in a cell-free assay. Daunorubicin is a topoisomerase II inhibitor that induces apoptosis.Daunorubicin (RP 13057) HCl can be used to induce animal models of Kidney Disease.
|
Many drugs already approved by FDA may have promise against COVID-19
|
|
S4157
|
Chloroquine diphosphate
|
Chloroquine diphosphate is a 4-aminoquinoline anti-malarial and anti-rheumatoid agent, also acting as an ATM activator. Chloroquine is also an inhibitor of toll-like receptors (TLRs).
|
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
|
|
S2823
|
Tideglusib
|
Tideglusib is an irreversible, non ATP-competitive GSK-3β inhibitor with IC50 of 60 nM in a cell-free assay; fails to inhibit kinases with a Cys homologous to Cys-199 located in the active site. Phase 2.
|
Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors
|
|
S2874
|
Camostat Mesilate
|
Camostat (FOY-305, FOY-S980) is a trypsin-like protease inhibitor, inhibits airway epithelial sodium channel (ENaC) function with IC50 of 50 nM, less potent to trpsin, prostasin and matriptase.
|
The Impact of Camostat Mesilate on COVID-19 Infection (CamoCO-19)
|
|
S8932
|
Remdesivir (GS-5734)
|
Remdesivir (GS-5734), a monophosphoramidate prodrug of an adenosine analog, is an investigational broad-spectrum antiviral agent with in vitro activity against multiple RNA viruses, including Ebola and CoV.
|
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
|
|
S5911
|
Bictegravir
|
Bictegravir (GS-9883) is a novel, potent, once-daily, unboosted inhibitor of HIV-1 integrase.
|
Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches
|
|
S1759
|
Pitavastatin calcium
|
Pitavastatin calcium, a novel member of the medication class of statins, is a calcium salt formulation of pitavastatin which is a highly effective HMG-CoA reductase inhibitor. Pitavastatin Calcium attenuates AGEs-induced mitophagy via inhibition of ROS generation. Pitavastatin Calcium induces autophagy and apoptosis.
|
Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches
|
|
S1680
|
Disulfiram
|
Disulfiram is a specific inhibitor of aldehyde-dehydrogenase (ALDH) with IC50 of 0.15 μM and 1.45 μM for hALDH1 and hALDH2, respectively. Disulfiram is used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram induces apoptosis. Disulfiram is also an inhibitor of pore formation by gasdermin D (GSDMD).
|
Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors
|
|
S1386
|
Nafamostat mesilate (FUT-175)
|
Nafamostat mesilate is a synthetic serine protease inhibitor, used as an anticoagulant during hemodialysis. Nafamostat mesylate blocks activation of SARS-CoV-2 and is investigated as a new treatment option for COVID-19. Nafamostat Mesilate attenuates inflammation and apoptosis.
|
Nafamostat inhibits SARS-CoV-2 infection, preventing COVID-19 transmission
|
|
S1706
|
Lamivudine
|
Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor, used for treatment of chronic HBV and HIV/AIDS. It works by blocking the HIV reverse transcriptase and hepatitis B virus polymerase.
|
COVID-19 Registered Trials – and analysis
|
|
S8279
|
Shikonin
|
Shikonin, a potent and specific Pyruvate kinase M2 (PKM2) inhibitor, is a major component of zicao (purple gromwell, the dried root of Lithospermum erythrorhizon), a Chinese herbal medicine with various biological activities. It is also an inhibitor of TMEM16A chloride channel activity using cell-based fluorescent-quenching assay. Shikonin exerts an anti-inflammatory effect by inhibiting tumor necrosis factor-α (TNF-α) and prevents activation of nuclear factor-κB (NF-κB) pathway via proteasome inhibition.
|
|
|
S1380
|
Lopinavir (ABT-378)
|
Lopinavir (ABT-378) is a potent HIV protease inhibitor with Ki of 1.3 pM in a cell-free assay.
|
Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicin
|
|
S2485
|
Mitoxantrone 2HCl
|
Mitoxantrone 2HCl is a dihydrochloride salt of Mitoxantrone. Mitoxantrone is an inhibitor of type II topoisomerase and protein kinase C (PKC) with IC50 of 8.5 μM for PKC. Mitoxantrone inhibits cell proliferative growth of MCF-7/wt cells with IC50 of 0.42 μM. Mitoxantrone also induces apoptosis.
|
Many drugs already approved by FDA may have promise against COVID-19
|
|
S4282
|
Nelfinavir Mesylate
|
Nelfinavir Mesylate is a potent HIV protease inhibitor with Ki of 2 nM.
|
Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches
|
|
S1185
|
Ritonavir
|
Ritonavir is a Cytochrome P450 3A and Protease Inhibitor; Also inhibits Cytochrome P450 2D6, P-Glycoprotein and induces Cytochrome P450 2C19, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 2B6 and UDP Glucuronosyltransferases. Ritonavir induces apoptosis.
|
Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicin
|
|
S1351
|
Ivermectin
|
Ivermectin is a glutamate-gated chloride channel (GluCls) activator, used as a broad-spectrum antiparasitic drug. Ivermectin (MK-933, IVM) is a specific positive allosteric effector of P2X4 and α7 nicotinic acetylcholine receptors (nAChRs). Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. Ivermectin induces autophagy through the AKT/mTOR signaling pathway and mitophagy.
|
Parasite Drug Shows Early Promise
Against COVID-19 in Vitro
|
|
S1401
|
Tenofovir
|
Tenofovir (GS-1278) blocks reverse transcriptase and hepatitis B virus infections.
|
COVID-19 Registered Trials – and analysis
|
|
S5250
|
Darunavir
|
Darunavir (TMC114,DRV) is a nonpeptidic HIV protease inhibitor, used to treat HIV infection.
|
Many drugs already approved by FDA may have promise against COVID-19
|
|
S7579
|
Ledipasvir (GS5885)
|
Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.
|
Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repur
|
|
S1538
|
Telaprevir
|
Telaprevir is an HCV NS3-4A serine protease inhibitor with IC50 of 0.35 μM.
|
α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment
|
|
S1183
|
Danoprevir
|
Danoprevir is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. Phase 2.
|
First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients
|
|
S2169
|
Rosuvastatin calcium
|
Rosuvastatin calcium is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM in a cell-free assay.
|
Many drugs already approved by FDA may have promise against COVID-19
|
|
S1289
|
Carmofur
|
Carmofur (HCFU) is a highly potent acid ceramidase inhibitor, used in the treatment of breast and colorectal cancer.
|
Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors
|
|
S7947
|
PX-12
|
PX-12 (DB05448, 1-methyl propyl 2-imidazolyl disulfide) is a potent thioredoxin-1 (Trx-1) inhibitor by irreversibly thioalkylation of Cys73 of Trx-1. Phase 2.
|
Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors
|
|
S3079
|
Atovaquone
|
Atovaquone (Atavaquone) is a medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia.
|
Many drugs already approved by FDA may have promise against COVID-19
|
|
S2926
|
TDZD-8
|
TDZD-8 (NP 01139) is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC.
|
Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors
|
|
S1691
|
Praziquantel
|
Praziquantel is an anthelmintic effective against flatworms.
|
Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches
|
|
S3733
|
Boceprevir
|
Boceprevir (EBP 520, SCH 503034) is an oral, direct acting hepatitis C virus (HCV) protease inhibitor with Ki value of 14 nM for NS3. It is used in combination with other antiviral agents in the treatment of chronic hepatitis C, genotype 1.
|
α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment
|
|
S3724
|
Velpatasvir
|
Velpatasvir (GS-5816,VEL) is a second-generation NS5A inhibitor that inhibits hepatitis C viral replication through acting on the crucial "membranous web" that facilitates RNA replication.
|
Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repur
|
|
S2071
|
Prulifloxacin (NM441)
|
Prulifloxacin (NM441, AF 3013), the prodrug of ulifloxacin, is a broad-spectrum oral fluoroquinolone antibacterial agent.
|
Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches
|
|
S9567
|
Indinavir Sulfate
|
Indinavir sulfate (Crixivan, L-735524, MK-639) is a specific and potent inhibitor of HIV-1 protease and is widely used in the treatment of AIDS.
|
Potential Therapeutic Agents for COVID-19 Based on the Analysis of Protease and RNA Polymerase Docking
|
|
S2079
|
Moexipril HCl
|
Moexipril HCl (RS-10085) is a potent orally active nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor, used for the treatment of hypertension and congestive heart failure.
|
Many drugs already approved by FDA may have promise against COVID-19
|
|
S3037
|
Bepotastine Besilate
|
Bepotastine Besilate (TAU 284) is a non-sedating, selective antagonist of histamine 1 (H1) receptor with pIC50 of 5.7.
|
Many drugs already approved by FDA may have promise against COVID-19
|
|
S5940
|
Bepotastine
|
Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor that is indicated in allergic rhinitis, urticaria, and pruritus associated with skin disease.
|
Many drugs already approved by FDA may have promise against COVID-19
|
|
S6676
|
Ebselen
|
Ebselen (DR 3305, SPI-1005, PZ-51, CCG-39161) is a small-molecule capsid inhibitor of HIV-1 Replication with IC50 of 46.1 nM in TR-FRET assay.
|
Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors
|
|
S8969
|
Molnupiravir (EIDD-2801)
|
Molnupiravir (EIDD-2801, MK-4482) is an orally bioavailable prodrug of the ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) with broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and the causative agent of COVID-19.
|
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
|
|
S1322
|
Dexamethasone
|
Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. Dexamethasone induces autophagy and mitophagy. Dexamethasone is tested in hospitalized patients with COVID-19 and is found to have benefits for critically ill patients.
|
Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial
|
